未经证实:癫痫影响全球约5000万人,导致重大医疗,金融,以及受影响患者及其家人的社会问题。迄今为止,癫痫的治疗主要是对症治疗,因为几乎没有有效的预防或改善疾病的干预措施.然而,最近的研究已经确定了癫痫发生的神经生物学机制,为研究提供新的药理靶点。当前的科学证据仍然分散在使用不同模型和实验设计的多项研究中。该综述汇编了抗癫痫研究的不同模型,并重点介绍了具有潜在癫痫发生修饰实验药物的特定化合物。它为未来癫痫研究的标准化提供了一个平台,可以对具有癫痫预防潜力的化合物进行更可靠的化合物分析。
未经授权:PubMed,OvidMEDLINE,和WebofScience从2007年到2021年进行了搜索。范围审查中包括了对癫痫发生的鼠模型的研究和明确详细的实验程序。总的来说,从14,983篇中选择51篇文章,然后按五个核心变量进行分组:(1)癫痫发作频率,(2)癫痫发作的严重程度,(3)自发性反复发作(SRS),(4)癫痫发作持续时间,和(5)苔藓纤维发芽(MFS)。根据实验模型区分变量,包括癫痫发作诱导方法,治疗时间表和数据收集时间表。通过五个核心变量对数据进行分类,并通过将原始处理值转换为其各自对照的百分比单位进行分析。
UNASSIGNED:当前癫痫发生模型的差异使潜在抗癫痫干预措施的研究间比较显著复杂化。根据我们的分析,许多化合物显示出降低由5个核心变量定义的癫痫发生特征的潜力.WIN55,212-2,阿司匹林,雷帕霉素,1400W,和LEV+BQ788被鉴定为具有潜在的有效抗癫痫特性的化合物。
UNASSIGNED:我们的综述强调了在癫痫研究中需要一致的方法,并为未来的研究提供了一种新的方法。不一致的实验设计阻碍了研究比较,减缓癫痫治疗的进展。如果研究界能够优化和标准化参数,如癫痫发作诱导方法,管理时间表,采样时间,和aniMal模型,更强大的荟萃分析和合作研究将随之而来。此外,一些化合物如雷帕霉素,WIN55,212-2,阿司匹林,1400W,LEV+BQ788在多个变量中显示抗癫痫基因调制。我们相信它们值得单独和协同地进一步研究。
UNASSIGNED: Epilepsy affects ~50 million people worldwide causing significant medical, financial, and sociologic concerns for affected patients and their families. To date, treatment of epilepsy is primarily symptomatic management because few effective preventative or disease-modifying interventions exist. However, recent research has identified neurobiological mechanisms of epileptogenesis, providing new pharmacologic targets to investigate. The current scientific evidence remains scattered across multiple studies using different model and experimental designs. The
review compiles different models of anti-epileptogenic investigation and highlights specific compounds with potential epileptogenesis-modifying experimental drugs. It provides a platform for standardization of future epilepsy research to allow a more robust compound analysis of compounds with potential for epilepsy prevention.
UNASSIGNED: PubMed, Ovid MEDLINE, and Web of Science were searched from 2007 to 2021. Studies with murine models of epileptogenesis and explicitly detailed experimental procedures were included in the scoping
review. In total, 51 articles were selected from 14,983 and then grouped by five core variables: (1) seizure frequency, (2) seizure severity, (3) spontaneous recurrent seizures (SRS), (4) seizure duration, and (5) mossy fiber sprouting (MFS). The variables were differentiated based on experimental models including methods of seizure induction, treatment schedule and timeline of data collection. Data was categorized by the five core variables and analyzed by converting original treatment values to units of percent of its respective control.
UNASSIGNED: Discrepancies in current epileptogenesis models significantly complicate inter-study comparison of potential anti-epileptogenic interventions. With our analysis, many compounds showed a potential to reduce epileptogenic characteristics defined by the five core variables. WIN55,212-2, aspirin, rapamycin, 1400W, and LEV + BQ788 were identified compounds with the potential of effective anti-epileptic properties.
UNASSIGNED: Our
review highlights the need for consistent methodology in epilepsy research and provides a novel approach for future research. Inconsistent experimental designs hinder study comparison, slowing the progression of treatments for epilepsy. If the research community can optimize and standardize parameters such as methods of seizure induction, administration schedule, sampling time, and aniMal models, more robust meta-analysis and collaborative research would follow. Additionally, some compounds such as rapamycin, WIN 55,212-2, aspirin, 1400W, and LEV + BQ788 showed anti-epileptogenic modulation across multiple variables. We believe they warrant further study both individually and synergistically.